NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

** HEALTH RESEARCH SHOWCASE THURSDAY 29 MAY 2025 **

Research Theme

Gene and Cell Therapy

You are here: Home > Research Overview > Gene and Cell Therapy

Gene and Cell Therapy

Gene therapies modify the genes of our cells to repair defects in our genetic material. The science of gene and cell engineering promises new treatments that may help people with many different diseases, across all fields of medicine, that result from defective genes.

Oxford has an established track record in creating new technologies in areas like genetics, editing of DNA and RNA and immune cell biology. This has often led to brand new therapies tested in human beings for the first time in clinical trials. Examples include treatments for cystic fibrosis and diseases of the retina.

We are using Oxford’s strength in experimental medicine to improve these technologies and carry out further research in medical settings. We hope that this will ultimately lead to new treatments available in the NHS.

Professor Robert MacLaren performing gene therapy

Eye therapies

A group of researchers in Oxford are working on cures for blindness.

Led by Professor Robert MacLaren, we have already made progress in developing prospective treatments for the most common causes of vision loss. These are age-related macular degeneration (AMD), the most common cause of visual loss in older people, and retinitis pigmentosa (RP), the most common cause of visual loss in younger people in the UK.

This work includes:

  • development of a single gene therapy treatment for AMD
  • the transplantation of photoreceptor cells derived from stem cells to treat RP

Read more about our eye therapy research


T cell therapies

Another significant area of our work in this theme relates to the modification or editing of T cells, white blood cells that play an important role in the body’s immune response.

Teams led by Professors Ronjon Chakraverty and Paresh Vyas are working to produce modified T cells that can act as an ‘off the shelf’ therapy for several blood cancers.

We have identified a genetic variant that protects against several autoimmune diseases, including multiple sclerosis. We are researching how we can edit the gene to include this protective variant in blood stem cells and transplant it into MS patients.

Read more about our work on T cells

Professor Charkraverty also leads a new Precision Cellular Therapeutics NIHR Blood and Transplant Research Unit which aims to develop new kinds of cell therapies for blood disorders and blood cancer, and improved systems for following up patients receiving treatment.


Gene editing

Several Oxford groups are designing technologies based on very precise CRISPR gene editing that are carried out in living tissue – not in the patients themselves, but in organoids – organ-like entities developed from cells taken from patients. This is an important step in validating the effectiveness of this gene editing approach.

Professor Matthew Wood has developed a method of modifying RNA that can be applied to a number of diseases, while Professor Deborah Gill is using gene editing to treat new-born respiratory distress syndrome. Professor MacLaren is also leading a research programme to develop gene editing tools to treat retinal degeneration.

Researchers in this theme have launched the UK’s first pilot study to conduct routine testing of new-born babies for spinal muscular atrophy (SMA), led by Professor Laurent Servais. We are carrying out an economic analysis of the impact this therapy which will inform the cost-effectiveness of such early genetic treatments for infants with rare diseases.

Gene and Cell Therapy

Gene and Cell Therapy icon
  • Gene and Cell Therapy
  • Eye therapies
  • T cell therapies
  • Contacts
  • Videos
  • News

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre